Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The latest deal over a CD47 asset has got investors wondering who could be next.
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.